RESUMO
Importance: Aminoglycosides are commonly prescribed antibiotics used for the treatment of neonatal sepsis. The MT-RNR1 m.1555A>G variant predisposes to profound aminoglycoside-induced ototoxicity (AIO). Current genotyping approaches take several days, which is unfeasible in acute settings. Objective: To develop a rapid point-of-care test (POCT) for the m.1555A>G variant before implementation of this technology in the acute neonatal setting to guide antibiotic prescribing and avoid AIO. Design, Setting, and Participants: This pragmatic prospective implementation trial recruited neonates admitted to 2 large neonatal intensive care units between January 6, 2020, and November 30, 2020, in the UK. Interventions: Neonates were tested for the m.1555A>G variant via the rapid POCT on admission to the neonatal intensive care unit. Main Outcomes and Measures: The primary outcome assessed the proportion of neonates successfully tested for the variant of all infants prescribed antibiotics. Secondary outcomes measured whether implementation was negatively associated with routine clinical practice and the performance of the system. The study was statistically powered to detect a significant difference between time to antibiotic administration before and after implementation of the MT-RNR1 POCT. Results: A total of 751 neonates were recruited and had a median (range) age of 2.5 (0-198) days. The MT-RNR1 POCT was able to genotype the m.1555A>G variant in 26 minutes. Preclinical validation demonstrated a 100% sensitivity (95% CI, 93.9%-100.0%) and specificity (95% CI, 98.5%-100.0%). Three participants with the m.1555A>G variant were identified, all of whom avoided aminoglycoside antibiotics. Overall, 424 infants (80.6%) receiving antibiotics were successfully tested for the variant, and the mean time to antibiotics was equivalent to previous practice. Conclusions and Relevance: The MT-RNR1 POCT was integrated without disrupting normal clinical practice, and genotype was used to guide antibiotic prescription and avoid AIO. This approach identified the m.1555A>G variant in a practice-changing time frame, and wide adoption could significantly reduce the burden of AIO.
Assuntos
Aminoglicosídeos , Ototoxicidade , Aminoglicosídeos/efeitos adversos , Antibacterianos/efeitos adversos , Genótipo , Humanos , Lactente , Recém-Nascido , Terapia Intensiva Neonatal , Sistemas Automatizados de Assistência Junto ao Leito , Estudos ProspectivosRESUMO
The development and properties of a liquid intravenous immunoglobulin (Gammaplex(®)), of high purity, stability and functional activity, is described. Virus and TSE reduction by specific steps in the process were evaluated by spiking studies using small-scale models. The removal of procoagulant activity was determined using immunochemical and functional activity assays. Neutralisation and opsonic activity were used to demonstrate the functional activity of the IgG. The final low pH formulated product was stable at room temperature and was of high purity and functional activity. Three dedicated virus inactivation steps, i.e. solvent detergent, low pH and virus filtration, were shown to be effective. When combined with the B + I ethanol precipitation step, this gave a total reduction of >21 to >24 log for the enveloped and >10 to >13 log for the non-enveloped viruses tested. Several steps in the process were shown to contribute to TSE removal using scrapie. Potential procoagulant activity including Factor XI/XIa, was reduced to very low/undetectable levels in the final product. A new high purity liquid IVIG product has been developed, of high purity and good functional activity and stability. The process includes various steps for the removal of pathogens and procoagulant activity.
Assuntos
Etanol/química , Imunoglobulinas Intravenosas/química , Inativação de Vírus , Estabilidade de Medicamentos , Humanos , Concentração de Íons de HidrogênioRESUMO
The theoretical potential for virus transmission by monoclonal antibody based therapeutic products has led to the inclusion of appropriate virus reduction steps. In this study, virus elimination by the chromatographic steps used during the purification process for two (IgG-1 & -3) monoclonal antibodies (MAbs) have been investigated. Both the Protein G (>7log) and ion-exchange (5 log) chromatography steps were very effective for eliminating both enveloped and non-enveloped viruses over the life-time of the chromatographic gel. However, the contribution made by the final gel filtration step was more limited, i.e., 3 log. Because these chromatographic columns were recycled between uses, the effectiveness of the column sanitization procedures (guanidinium chloride for protein G or NaOH for ion-exchange) were tested. By evaluating standard column runs immediately after each virus spiked run, it was possible to directly confirm that there was no cross contamination with virus between column runs (guanidinium chloride or NaOH). To further ensure the virus safety of the product, two specific virus elimination steps have also been included in the process. A solvent/detergent step based on 1% triton X-100 rapidly inactivating a range of enveloped viruses by >6 log inactivation within 1 min of a 60 min treatment time. Virus removal by virus filtration step was also confirmed to be effective for those viruses of about 50 nm or greater. In conclusion, the combination of these multiple steps ensures a high margin of virus safety for this purification process.
Assuntos
Anticorpos Monoclonais/isolamento & purificação , Cromatografia Líquida/métodos , Ultrafiltração/métodos , Inativação de Vírus , Vírus/química , Vírus/isolamento & purificação , OctoxinolRESUMO
Various chromatographic procedures are used during the purification and manufacture of plasma products such as coagulation factors. These steps contribute to the overall safety of such products by removing potential virus contamination. Virus removal by two affinity chromatography procedures, i.e. monoclonal antibody chromatography and metal chelate chromatography (immobilised metal ion affinity chromatography), used during the manufacture of the high purity factor VIII (Replenate®) and factor IX (Replenine®-VF), respectively, has been investigated. In addition, as these columns are recycled after use, the effectiveness of the sanitisation procedures for preventing possible cross-contamination, has also been investigated. Both chromatographic steps proved effective for eliminating a range of model enveloped and non-enveloped viruses by 4 to >6 and 5 to >8 log for the monoclonal and metal chelate columns, respectively. The effectiveness of the relatively mild column sanitisation conditions used, i.e. ethanol for factor IX and acetic acid for factor VIII, was confirmed using non-spiked column runs. The chemicals used contributed to virus elimination by inactivation and/or by physical removal of the virus. In summary, these studies demonstrate that potential virus contamination between chromatographic runs can be prevented when an effective column recycling and sanitisation procedure is included.
Assuntos
Cromatografia de Afinidade/instrumentação , Desinfecção/métodos , Contaminação de Medicamentos/prevenção & controle , Fator IX/química , Fator VIII/química , Vírus/isolamento & purificação , Animais , Fatores de Coagulação Sanguínea/química , Células Cultivadas , Chlorocebus aethiops , Cromatografia por Troca Iônica/instrumentação , Cricetinae , Cães , Contaminação de Equipamentos/prevenção & controle , Reutilização de Equipamento , Células Vero , Inativação de VírusRESUMO
Virus reduction by several steps in the manufacturing process for the intravenous immunoglobulin Vigam(®), has been investigated. The solvent/detergent step based on treatment with 0.3% tri-n-butyl phosphate and 1% polysorbate 80 at 37 °C, was confirmed to be effective for a range of enveloped viruses. Virus infectivity was undetectable i.e. >6 log inactivation within 30 min of the standard 6 h process. This was consistent over the range of conditions tested i.e. solvent/detergent and protein concentration, temperature and pH. The ion-exchange chromatography step in the process was also able to remove some viruses. Virus spiked followed by blank column runs confirmed the effectiveness of the sanitisation step for ensuring there was no virus cross contamination between column runs. The terminal low pH incubation step was also able to inactivate enveloped viruses, as well as some non-enveloped viruses. The combination of these three steps ensures a high margin of virus safety for this product.
Assuntos
Detergentes/farmacologia , Imunoglobulinas Intravenosas/química , Solventes/farmacologia , Inativação de Vírus , Fracionamento Químico/métodos , Cromatografia por Troca Iônica/métodos , Relação Dose-Resposta a Droga , Contaminação de Medicamentos/prevenção & controle , Humanos , Concentração de Íons de Hidrogênio , Imunoglobulinas Intravenosas/isolamento & purificação , Imunoglobulinas Intravenosas/normas , Limite de Detecção , Temperatura , Carga Viral/efeitos dos fármacos , Vírus/efeitos dos fármacos , Vírus/isolamento & purificaçãoRESUMO
Non-enveloped viruses such as HAV and B19 are of potential concern in plasma products. In the case of albumin, pasteurisation at 60 °C for 10 h is generally used for virus inactivation. However this procedure is only partially effective against some non-enveloped viruses. Using a range of non-enveloped viruses i.e. HAV, SV40, CPV, treatment at a high pH of about 9.5 and a temperature of 60 °C for 10 h was found to be effective for virus inactivation. These extreme conditions caused no increase in aggregate composition of the albumin. In addition the albumin composition was stable over a period of at least 6 months. The ligand binding properties of the albumin, as determined using the dye phenol red, were also not affected by this treatment. This procedure has the potential for increasing the spectrum of viruses inactivated by the 60 °C pasteurisation step.
Assuntos
Albuminas/farmacologia , Álcalis/farmacologia , Temperatura Alta , Inativação de Vírus , Albuminas/química , Albuminas/metabolismo , Animais , Bocavirus/efeitos dos fármacos , Bocavirus/fisiologia , Células Cultivadas , Chlorocebus aethiops , Vírus da Hepatite A/efeitos dos fármacos , Vírus da Hepatite A/fisiologia , Humanos , Concentração de Íons de Hidrogênio , Parvovirus Canino/efeitos dos fármacos , Parvovirus Canino/fisiologia , Estabilidade Proteica/efeitos dos fármacos , Vírus 40 dos Símios/efeitos dos fármacos , Vírus 40 dos Símios/fisiologia , Células Vero , Inativação de Vírus/efeitos dos fármacosRESUMO
Virus removal from a high purity factor IX, Replenine-VF, by filtration using a Planova 15N filter has been investigated. A wide range of relevant and model enveloped and non-enveloped viruses, of various sizes, were effectively removed by this procedure. Virus removal was confirmed to be effective when different batches of filter were challenged with poliovirus-1. It was confirmed that intentionally modified filters that failed the leakage test had completely lost the ability to remove virus, thus confirming that this test demonstrates gross filter failure. In the case of the more sensitive integrity test based on gold particle removal, it was found that a pre-wash step was not essential. Planova filters that had been modified by sodium hydroxide treatment to make them more permeable, and filters manufactured with varying pore-sizes over the range of 15-35 nm, were tested. The integrity test value that resulted in the removal of >4 log(10) of poliovirus-1 from the product correlated with that recommended by the filter manufacturer. Virus removal from the product was not influenced by filter load mass, flow-rate or pressure. These studies confirm the robustness of this filtration procedure and allow suitable process limits to be set for this manufacturing step.
Assuntos
Indústria Farmacêutica/normas , Fator IX/química , Filtração/métodos , Técnicas Microbiológicas/normas , Vírus/isolamento & purificação , Animais , Bovinos , Células Cultivadas , Chlorocebus aethiops , Cricetinae , Descontaminação/métodos , Contaminação de Medicamentos/prevenção & controle , Indústria Farmacêutica/métodos , Fator IX/normas , Humanos , Manufaturas/normas , Manufaturas/virologia , Tamanho da Partícula , Poliovirus/isolamento & purificação , Valor Preditivo dos Testes , Sensibilidade e Especificidade , Células VeroRESUMO
The removal of the abnormal form of prion protein i.e. PrP(SC) by filtration steps in the plasma fractionation process has been investigated by immuno-Western blotting. Depth filtration has been shown to be capable of removing scrapie by 2-3 log from certain plasma product intermediates. These include cryoprecipitate supernatant, used for the manufacture of immunoglobulin and albumin, and albumin fraction V, by filtration using Pall Seitz or 3m Cuno depth filters respectively. However no significant removal occurred with immunoglobulin Fraction II after Cuno depth filtration. When 0.2 microm PVDF and Nylon membrane filters were tested, the removal of TSEs from 20% albumin was limited i.e. 0.6-1.3 log. However under protein free conditions using phosphate buffered saline, filtration was not effective in the case of a PVDF filter but very effective i.e. >2.9 log in the case of a Nylon filter.
Assuntos
Produtos Biológicos/química , Hemofiltração/métodos , Plasma/química , Proteínas PrPSc/isolamento & purificação , Doenças Priônicas/prevenção & controle , Produtos Biológicos/normas , Contaminação de Medicamentos/prevenção & controle , Humanos , Membranas Artificiais , Filtros Microporos , Polivinil/farmacologia , Doenças Priônicas/metabolismo , Titulometria/métodosRESUMO
Treatment with solvent/detergent is a widely used method for ensuring the virus safety of plasma products. In the present study, virus inactivation by a novel solvent/detergent combination, i.e. TnBP (tri-n-butyl phosphate) and polysorbate 20 during the manufacture of the factor VIII/VWF concentrate Optivate has been investigated. The inactivation of most enveloped viruses was rapid, i.e. > 5 log in 2 min, although the inactivation of vaccinia virus was slower, i.e. 4 log in 1h. Virus inactivation was effective over a wide range of conditions, i.e. solvent/detergent concentration, protein concentration and temperature, irrespective of whether tested individually or in combination. This confirms the effectiveness and robustness of this alternative version of the solvent/detergent procedure, and allows appropriate control limits to be set for this manufacturing step. Polysorbate 20 provides an alternative to the non-ionic detergents currently in use with the solvent/detergent procedure.
Assuntos
Detergentes/farmacologia , Fator VIII/normas , Polissorbatos/farmacologia , Inativação de Vírus , Fator de von Willebrand/normas , Animais , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Precipitação Química , Chlorocebus aethiops , Combinação de Medicamentos , Contaminação de Medicamentos/prevenção & controle , Fator VIII/síntese química , Fator VIII/química , Organofosfatos/farmacologia , Solventes/farmacologia , Temperatura , Células Vero , Viroses/sangue , Viroses/patologia , Viroses/prevenção & controle , Fator de von Willebrand/síntese química , Fator de von Willebrand/químicaRESUMO
Virus inactivation by solvent/detergent treatment using 0.3% tri-n-butyl phosphate and 1% Triton X-100 in the high purity factor VIII concentrate Replenate has been investigated. A wide range of model enveloped viruses were confirmed to be inactivated by >4 to >6 log after 30 min at 22 degrees C under standard conditions. Using Sindbis as a representative enveloped virus, the effect of various parameters on the inactivation process was tested. Virus inactivation was confirmed to be effective in different batches of product and was not influenced by changing the process conditions with regard to protein and salt concentration or pH. Virus inactivation was effective even at a temperature as low as 4-5 degrees C. Although solvent/detergent concentration was the most critical parameter, a concentration as low as 0.15% TnBP/0.5% Triton X-100 was still completely effective. At a lower concentration an extended incubation period was required. These studies demonstrate the robustness of this solvent/detergent procedure based on Triton X-100 and allow suitable process limits to be set for this manufacturing step.
Assuntos
Fator VIII/metabolismo , Octoxinol/farmacologia , Solventes/farmacologia , Inativação de Vírus/efeitos dos fármacos , Animais , Linhagem Celular , Cricetinae , Concentração de Íons de Hidrogênio , Sais , TemperaturaRESUMO
Virus inactivation by a number of protein denaturants commonly used in gel affinity chromatography for protein elution and gel recycling has been investigated. The enveloped viruses Sindbis, herpes simplex-1 and vaccinia, and the non-enveloped virus polio-1 were effectively inactivated by 0.5 M sodium hydroxide, 6 M guanidinium thiocyanate, 8 M urea and 70% ethanol. However, pH 2.6, 3 M sodium thiocyanate, 6 M guanidinium chloride and 20% ethanol, while effectively inactivating the enveloped viruses, did not inactivate polio-1. These studies demonstrate that protein denaturants are generally effective for virus inactivation but with the limitation that only some may inactivate non-enveloped viruses. The use of protein denaturants, together with virus reduction steps in the manufacturing process should ensure that viral cross contamination between manufacturing batches of therapeutic biological products is prevented and the safety of the product ensured.